These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1464509

  • 1. Efficacy of adjunctive intrathrombic heparin with pulse spray thrombolysis in rabbit inferior vena cava thrombosis.
    Valji K, Bookstein JJ.
    Invest Radiol; 1992 Nov; 27(11):912-7. PubMed ID: 1464509
    [Abstract] [Full Text] [Related]

  • 2. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis.
    Valji K, Arun K, Bookstein JJ.
    J Vasc Interv Radiol; 1995 Nov; 6(1):91-5. PubMed ID: 7703589
    [Abstract] [Full Text] [Related]

  • 3. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
    Valji K, Bookstein JJ.
    Radiology; 1993 Mar; 186(3):873-6. PubMed ID: 8430201
    [Abstract] [Full Text] [Related]

  • 4. Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
    Lim GM, Bookstein JJ.
    J Vasc Interv Radiol; 1998 Mar; 9(4):618-25. PubMed ID: 9684833
    [Abstract] [Full Text] [Related]

  • 5. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques.
    Valji K, Bookstein JJ, Roberts AC, Oglevie SB, Pittman C, O'Neill MP.
    AJR Am J Roentgenol; 1995 Jun; 164(6):1495-500; discussion 1501-3. PubMed ID: 7754901
    [Abstract] [Full Text] [Related]

  • 6. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.
    Bookstein JJ, Bookstein FL.
    J Vasc Interv Radiol; 2000 Mar; 11(3):299-303. PubMed ID: 10735423
    [Abstract] [Full Text] [Related]

  • 7. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

  • 8. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D.
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 12. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
    Uriuda Y, Wang QD, Hatori N, Nordlander R, Sjöquist PO, Mattsson C, Rydén L.
    J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen-enriched pulse-spray thrombolysis with tPA: further developments.
    Bookstein JJ, Bookstein FL.
    J Vasc Interv Radiol; 2000 Mar; 11(10):1353-62. PubMed ID: 11099249
    [Abstract] [Full Text] [Related]

  • 14. The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke.
    Bednar MM, Quilley J, Russell SR, Fuller SP, Booth C, Howard D, Gross CE.
    Neurosurgery; 1996 Aug; 39(2):352-9. PubMed ID: 8832673
    [Abstract] [Full Text] [Related]

  • 15. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy.
    Dillon PW, Fox PS, Berg CJ, Cardella JF, Krummel TM.
    J Pediatr Surg; 1993 Oct; 28(10):1264-8; discussion 1268-9. PubMed ID: 8263684
    [Abstract] [Full Text] [Related]

  • 16. Acute iliofemoral venous thrombosis in patients with atresia of the inferior vena cava can be treated successfully with catheter-directed thrombolysis.
    Broholm R, Jørgensen M, Just S, Jensen LP, Bækgaard N.
    J Vasc Interv Radiol; 2011 Jun; 22(6):801-5. PubMed ID: 21459610
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of Pharmacomechanical Catheter-directed Thrombolysis for Acute and Subacute Inferior Vena Cava Thrombosis: A Retrospective Evaluation in a Single Institution.
    Ye K, Qin J, Yin M, Liu X, Lu X.
    Eur J Vasc Endovasc Surg; 2017 Oct; 54(4):504-512. PubMed ID: 28801136
    [Abstract] [Full Text] [Related]

  • 18. Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
    Kornowski R, Glikson M, Hasdai D, Chernine A, Ohad D, Battler A.
    Eur Heart J; 1994 Apr; 15(4):541-6. PubMed ID: 8070483
    [Abstract] [Full Text] [Related]

  • 19. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.
    Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, Loscalzo J.
    Circ Res; 1992 Apr; 70(4):829-34. PubMed ID: 1551206
    [Abstract] [Full Text] [Related]

  • 20. Pulse-spray thrombolysis of inferior vena cava thrombosis complicating filter placement.
    Hansen ME, Miller GL, Starks KC.
    Cardiovasc Intervent Radiol; 1994 Apr; 17(1):38-40. PubMed ID: 8187132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.